Blog | The Latest
MPS vs. NGS: What's the Difference?
Massively Parallel Sequencing, also called Next Generation Sequencing (NGS), has the potential to assist forensic DNA laboratories in cases involving human identification, kinship and ancestral origin at a faster pace and cheaper cost.
It also has the potential to solve some of the biggest challenges facing forensic scientists, namely the reality of working with degraded DNA samples or samples containing DNA from multiple contributors.
The science is a game-changing reality, but many in the forensic community refer to it by different names, which can cause some confusion. So, why the differing names?
Here’s our take.
What is Massively Parallel Sequencing?
The term “Massively Parallel Sequencing” is used to describe the method of high-throughput DNA sequencing to determine the entire genomic sequence of a person or organism. This method processes millions of reads, or DNA sequences, in parallel instead of processing single amplicons that generate a consensus sequence. The result is a higher resolution of every sample.
This process gives MPS vastly more resolution than traditional Sanger-based capillary electrophoresis (CE) technologies. The impact of this is huge for the forensic community: scientists can extract meaningful information from full or partial DNA samples even when databases do not confirm a match.
What is Next Generation Sequencing?
In short, the same exact thing. Consider this definition:
"Next-generation sequencing refers to non-Sanger-based high-throughput DNA sequencing technologies. Millions or billions of DNA strands can be sequenced in parallel, yielding substantially more throughput and minimizing the need for the fragment-cloning methods that are often used in Sanger sequencing of genomes."
The two terms are used interchangeably. Historically, Next Generation Sequencing was used as the catchall term for high-throughput DNA sequencing. Over the past few years, however, the term MPS is beginning to have broader adoption among forensic scientists.
Why So Many Names for the Same Technology?
The forensic community refers to MPS by several names, including Next Generation Sequencing (NGS), and High Throughput Sequencing (HTS). The reason for the interchangeable names may be found in the history of genomic sequencing.
DNA sequencing has gone through many evolutions since its beginnings in the late 1970s.
In the earliest days, a scientist by the name of Fred Sanger learned how to sequence the first whole DNA genome. He quickly went on to develop DNA sequencing technology, using a technique called the chain termination method. This is now seen as the “first generation technology” of genome sequencing.
This method had a significant disadvantage: it was painstakingly slow, expensive and it relied on radioactive materials. Throughout the 80s and 90s, new technologies emerged that built upon Sanger’s approach in ways that increased the throughput and safety of DNA sequencing through automated, capillary electrophoresis (CE) sequencing. For decades, this became the primary method for genomic sequencing.
But limitations continued to persist. While faster and less expensive than Sanger’s technique, CE sequencing was still slow and expensive. Results took years to produce and millions of dollars.
In the early 2000s, new technology emerged that sequenced DNA in parallel – greatly increasing the speed of throughput and significantly lowering the costs associated with DNA sequencing. Scientists could run sequences in days instead of years, for thousands of dollars instead of millions. The shift was so radical that this became known as the “Next Generation” of genomic sequencing.
And that name stuck. Until now.
The Next Generation of DNA Sequencing
The next generation will be defined less by technology, and more by adoption and application.
While academic and research organizations are well-versed in MPS methods and technologies, the forensic community have yet to fully adopt the method. That’s especially true in the realm of forensic investigation – where MPS can have a huge impact on investigations.
Here’s why: while the technology is promising, it has yet to be validated in the rigid accredited workflows required for investigative agencies and crime labs. NGS technology introduces methodology, instrumentation, workflow and data management and reporting practices that are different from the well-established conventional DNA technology practices used in forensic DNA laboratories. In addition, peer-reviewed publications detailing comprehensive NGS testing relative to the DNA Quality Assurance Standards, necessary to evaluate a new or novel technology for introduction in forensic science and criminal justice arenas, are limited.
But progress is being made.
Battelle has completed a 19-month Feasibility & Guidance study, conducted on behalf of the National Institute of Justice, involving a variety of federal, state and local forensic laboratories. The study evaluates existing MPS genotyping systems (reagents, instrumentation and workflows). Want the cliff notes version? Join our live webinar that profiles key findings from the report.
In addition, workshops have been organized at international meetings (like ISHI) the last few years to increase awareness of the strengths and weaknesses of the technology and how it relates to current capillary electrophoresis approaches for genotyping. With the release of the NIJ report, thought leaders from around the forensic community can come together to develop strategies for MPS implementation.
The forensic community is getting closer to taking MPS mainstream. Our next big step is defining an implementation roadmap for the adoption of MPS technology within investigative workflows.
Why Massively Parallel Sequencing
At Battelle, we choose to refer to this high-throughput, low-cost, extremely-accurate genome testing as Massively Parallel Sequencing. The reason is quite simple – the name is simply a more accurate depiction of the technology. We are living in the next generation of DNA sequencing. The question is, will we take advantage?
The Big Question Facing Forensic DNA Laboratories
The evolution in DNA sequencing is not only giving scientists more results in faster time, it’s shifting the way that scientists think about genetic information. And it’s providing remarkable new possibilities for forensic case work, which can have a huge impact of crime fighting success and community safety.
Will the forensic community take advantage?
Battelle has been working with other U.S. government agencies and the Ohio Bureau of Criminal Investigation to evaluate MPS and develop optimized workflows and validation methods. This work, coupled with the NIJ study, are informing the development of recommendations and training programs for forensic labs wishing to implement MPS.
Receive updates from Battelle for an all-access pass to the incredible work of Battelle researchers.
View all blog articles
Events | Upcoming
Chicago, IL March 24 - 27, 2024View Event
Orlando, FL May 14 - 16, 2024View Event
National Security Case Study View Case Study
Environment Case Study View Case Study
Industry Case Study View Case Study
Feb 26, 2024 HealthFor eco-conscious consumers of personal medical devices, recycling options are limited. Some companies are trying to change that.View News Article
View all news articles
Feb 27, 2024 National Security
Battelle Hosted Spring Training Camp for the U.S. Cyber Team to Help Train the Next Generation of Cyber ExpertsThe U.S. Cyber Games Season III team joined Battelle cyber experts at a spring training event in preparation for the International Cybersecurity Championship set to take place later thi...
Jan 17, 2024 National Security
Battelle RavenStar™ Antenna Technology Achieves Telecommunications Industry First at Famed VT-ARC Testing SiteBattelle RavenStar™ antenna technology successfully demonstrated ultra-wideband capabilities at the Virginia Tech Applied Research Corporation’s (VT-ARC) 5G/XG field test site near Blac...
Dec 13, 2023 Health
Battelle Brings Specialized Engineering Capabilities and Clinical Study Expertise to Collaboration with Spark Biomedical on Department of Defense $1.15 Million GrantBattelle and Spark Biomedical, Inc. are collaborating on the development of a non-invasive device to tackle the harmful effects of Acute Stress Reactions (ASR).
Dec 12, 2023 EnvironmentBattelle and its spinoff company Revive Environmental have been chosen to participate in the United States Department of Defense (DoD) new cohort of prototype projects to demonstra...
Dec 04, 2023Battelle announced today that it received a score of 100 on the Human Rights Campaign Foundation’s 2023-2024 Corporate Equality Index (CEI).
Nov 28, 2023Battelle announces the election of two distinguished industry leaders, Calvin Butler and Jeff Edwards, to its Board of Directors.
Nov 20, 2023 Health
Battelle, Andelyn Biosciences, and AmplifyBio Awarded Task Orders for Plasmid and Suspension AAV Vector Manufacturing and IND-enabling Studies from the National Institute of Neurological Disorders and Stroke (NINDS)Battelle, Andelyn Biosciences, Inc., and AmplifyBio, have been awarded a new task order from the National Institute of Neurological Disorders and Stroke (NINDS) to manufacture suspensio...
Nov 08, 2023 National SecurityBattelle was awarded $6.1 million from the Biomedical Advanced Research and Development Authority (BARDA) to advance human lung and airway tissue chip platform technology.
View all Press releases
Visit our youtube page
Sign Up for Battelle Updates